AR034985A1 - Compuesto biciclico; produccion y uso del mismo - Google Patents

Compuesto biciclico; produccion y uso del mismo

Info

Publication number
AR034985A1
AR034985A1 ARP020102986A ARP020102986A AR034985A1 AR 034985 A1 AR034985 A1 AR 034985A1 AR P020102986 A ARP020102986 A AR P020102986A AR P020102986 A ARP020102986 A AR P020102986A AR 034985 A1 AR034985 A1 AR 034985A1
Authority
AR
Argentina
Prior art keywords
ring
substituted
compound
group
production
Prior art date
Application number
ARP020102986A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR034985A1 publication Critical patent/AR034985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)

Abstract

La presente provee un nuevo compuesto cíclico que tiene una actividad antagonista del CCR, especialmente una actividad antagonista del CCR5, y el uso del mismo. El compuesto de la presente está representado por la fórmula (1) en donde: R1 es un anillo de 5 a 6 miembros que puede estar sustituido; X1 es un enlace o similares; el anillo A es un anillo de 5 a 6 miembros que puede estar sustituido; el anillo B es un anillo de 8 a 10 miembros que puede estar sustituido; X2 es un grupo bivalente de 1 a 4 átomos; Z1 es un grupo de anillo cíclico bivalente o similares; Z2 es un enlace o similares; y R2 es un grupo amino, un grupo heterocíclico con contenido de nitrógeno que puede estar sustituido, o una sal del mismo.
ARP020102986A 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo AR034985A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12

Publications (1)

Publication Number Publication Date
AR034985A1 true AR034985A1 (es) 2004-03-24

Family

ID=26620186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102986A AR034985A1 (es) 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo

Country Status (13)

Country Link
US (7) US7371772B2 (es)
EP (3) EP1889839B1 (es)
JP (4) JP4316203B2 (es)
AR (1) AR034985A1 (es)
AT (2) ATE460406T1 (es)
AU (1) AU2002328092A1 (es)
CA (2) CA2459172C (es)
DE (1) DE60235632D1 (es)
DK (2) DK2206702T3 (es)
ES (2) ES2339340T3 (es)
PE (1) PE20030329A1 (es)
PT (2) PT1423376E (es)
WO (1) WO2003014105A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235632D1 (de) * 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
CA2479071A1 (en) * 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
WO2004069833A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 縮環ピリジン誘導体、その製造法および用途
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
US20060178359A1 (en) * 2003-02-07 2006-08-10 Mitsuru Shiraishi Tricyclic compound, process for producing the same, and use
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
JP5057779B2 (ja) * 2004-03-24 2012-10-24 武田薬品工業株式会社 エマルション安定化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
CA2741060A1 (en) * 2008-10-17 2010-04-22 Invasc Therapeutics, Inc. Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
SG11201607859SA (en) * 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
CN106999593A (zh) 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
JP6716568B2 (ja) * 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
RU2722641C2 (ru) 2015-02-10 2020-06-02 Тобира Терапьютикс, Инк. Ценикривирок для лечения заболеваний печени и перитонита
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
CA3028151A1 (en) * 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
RU2019109019A (ru) 2016-08-31 2020-10-01 Тобира Терапьютикс, Инк. Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата
ES2906992T3 (es) * 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
BR112019017314A2 (pt) 2017-02-24 2020-04-14 Genfit composições farmacêuticas para terapia de combinação
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
US20230002360A1 (en) * 2019-06-24 2023-01-05 Shenzhen Lingfang Biotech Co.,Ltd Heterocycloalkyl compounds as CCR2 / CCR5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
BR112022023732A2 (pt) * 2020-05-22 2022-12-20 Medshine Discovery Inc Derivado de piridina e sua aplicação
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
CN118987211B (zh) * 2023-05-22 2025-09-19 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
AU9461898A (en) 1997-10-20 1999-05-10 Dainippon Pharmaceutical Co. Ltd. Stable drug composition
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
WO2000010965A2 (en) * 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
WO2000037455A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
JP4807687B2 (ja) 1999-04-12 2011-11-02 塩野義製薬株式会社 塩基性疎水性医薬化合物の医薬組成物の製造法
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (en) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
DE60235632D1 (de) * 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
CA2479071A1 (en) 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
JP5057779B2 (ja) * 2004-03-24 2012-10-24 武田薬品工業株式会社 エマルション安定化製剤
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
SG10201510402WA (en) 2010-11-18 2016-01-28 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
JP6178788B2 (ja) 2011-06-27 2017-08-09 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド
JP6391674B2 (ja) 2013-05-15 2018-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロック組成物並びにその製造及び使用方法
SG11201607859SA (en) 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
RU2722641C2 (ru) 2015-02-10 2020-06-02 Тобира Терапьютикс, Инк. Ценикривирок для лечения заболеваний печени и перитонита

Also Published As

Publication number Publication date
PE20030329A1 (es) 2003-05-12
EP1423376A1 (en) 2004-06-02
HK1142886A1 (en) 2010-12-17
ATE539062T1 (de) 2012-01-15
US20190038604A1 (en) 2019-02-07
US8183273B2 (en) 2012-05-22
EP1889839B1 (en) 2013-11-06
EP1889839A1 (en) 2008-02-20
JP2013136629A (ja) 2013-07-11
US7371772B2 (en) 2008-05-13
JP2009209154A (ja) 2009-09-17
US20120232028A1 (en) 2012-09-13
JP4316203B2 (ja) 2009-08-19
EP2206702A1 (en) 2010-07-14
US10045968B2 (en) 2018-08-14
DK2206702T3 (da) 2012-02-13
JP4358851B2 (ja) 2009-11-04
ES2376855T3 (es) 2012-03-20
DE60235632D1 (de) 2010-04-22
US20090030032A1 (en) 2009-01-29
CA2459172A1 (en) 2003-02-20
DK1423376T3 (da) 2010-06-28
PT2206702E (pt) 2012-02-03
PT1423376E (pt) 2010-04-12
ATE460406T1 (de) 2010-03-15
EP1423376B1 (en) 2010-03-10
CA2607992A1 (en) 2003-02-20
US8362058B2 (en) 2013-01-29
ES2339340T3 (es) 2010-05-19
AU2002328092A1 (en) 2003-02-24
JP5275148B2 (ja) 2013-08-28
US20200297700A1 (en) 2020-09-24
EP2206702B1 (en) 2011-12-28
US20080161287A1 (en) 2008-07-03
WO2003014105A1 (en) 2003-02-20
US8741943B2 (en) 2014-06-03
JP2003335776A (ja) 2003-11-28
WO2003014105A9 (en) 2003-11-20
US20160008326A1 (en) 2016-01-14
CA2459172C (en) 2011-07-05
JP2007084578A (ja) 2007-04-05
US20040259876A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
AR034985A1 (es) Compuesto biciclico; produccion y uso del mismo
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
TW201129553A (en) Dipeptidyl peptidase inhibitors
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
ECSP045221A (es) Sales de valsartan
DE60132975D1 (de) Neue substanzen und verbindungen als protease-inhibitoren
BR0311771A (pt) Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
AR011913A1 (es) Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
PT1200426E (pt) Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE404538T1 (de) Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
DE60318826D1 (de) Alkoxypyridinderivate
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
GT200300183A (es) Nuevos agonistas ppar-alfa y ppar-gamma
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal